Rapid Micro Biosystems (RPID) CEO awarded 264K RSUs and 528K-option grant

Rhea-AI Filing Summary

Rapid Micro Biosystems, Inc. President and CEO Robert G. Spignesi Jr., who is also a director, reported equity compensation awards. He received 264,000 shares of Class A common stock on February 11, 2026 as a grant of restricted stock units that vest over three years.

The RSUs vest in three annual installments, with 33.4% vesting on the first anniversary of the February 11, 2026 grant date and 33.3% vesting on each of the next two anniversaries, subject to continued service. He was also granted a stock option covering 528,000 shares at an exercise price of $4.20 per share, vesting in 48 equal monthly installments starting March 11, 2026 and expiring February 10, 2036. Following these awards, he directly beneficially owns 1,226,097 shares of Class A common stock and 528,000 stock options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Spignesi Robert G. Jr.

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	528,000	$0.00	--
Grant/Award	Class A Common Stock	264,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 528,000 shares (Direct); Class A Common Stock — 1,226,097 shares (Direct)

Footnotes (1)

1. Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date. The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spignesi Robert G. Jr.

(Last) (First) (Middle)

C/O RAPID MICRO BIOSYSTEMS, INC.

25 HARTWELL AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPID MICRO BIOSYSTEMS, INC. [ RPID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/11/2026		A		264,000(1)	A	$0	1,226,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.2	02/11/2026		A		528,000		(2)	02/10/2036	Class A Common Stock	528,000	$0	528,000	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.

2. The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.

Remarks:

	/s/ Sean M. Wirtjes, Attorney-in-Fact for Robert G. Spignesi, Jr.	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Rapid Micro Biosystems (RPID) grant to its CEO?

Rapid Micro Biosystems granted its CEO 264,000 Class A common shares as restricted stock units and a stock option for 528,000 shares. Both awards were granted on February 11, 2026, as part of his equity-based compensation package disclosed in the insider transaction report.

How do the RSUs granted to the RPID CEO vest over time?

The 264,000 RSUs vest in three annual installments tied to the February 11, 2026 grant date. 33.4% vest on the first anniversary, and 33.3% vest on each of the second and third anniversaries, provided the CEO remains in continuous service on each vesting date.

What are the key terms of the 528,000-share stock option granted by RPID?

The stock option covers 528,000 shares of Class A common stock at a $4.20 exercise price. It vests in 48 substantially equal monthly installments, with the first installment vesting on March 11, 2026, and the option expires on February 10, 2036 if not exercised.

How many Rapid Micro Biosystems shares does the CEO own after these grants?

After the reported transactions, the CEO directly beneficially owns 1,226,097 shares of Class A common stock. He also directly holds a stock option for 528,000 shares, reflecting his equity stake and incentive alignment with the company’s long-term performance.

Is the RPID CEO’s reported transaction a purchase or an equity grant?

The reported transactions are equity grants, not open-market purchases. Both the 264,000 RSUs and the 528,000-share stock option were acquired at a price of $0 per share as compensation awards, categorized as grants or other acquisitions in the insider filing.